SEC Form 4 · accession 0001209191-17-019350
Sierra Oncology, Inc. · SRRA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Nicholas Glover
Officer — CEO and President · Director
Period of report
Mar 6, 2017
Accepted (ET)
Mar 8, 2017 · 5:33 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001290149
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $1.45 | Mar 6, 2017 | A | 195,000 | A | — | Mar 6, 2027 | Common Stock | 195,000 | 195,000 | D |
Explanation of responses
- F1The option vests as to 25% of the total shares on January 1, 2018, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on January 1, 2021, subject to the reporting person's provision of service to the issuer on each vesting date.